Northwire Canada EditionSunday, July 12, 2026
Northwire
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other

BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer

BIOV · Price

Executive Summary

  • BioVaxys reported positive Phase 2 data for maveropepimut‑S (MVP‑S) combined with pembrolizumab and low‑dose cyclophosphamide in metastatic bladder cancer.
  • Among 17 evaluable patients, two achieved confirmed complete responses and three had partial responses; all five responders included two who were refractory to prior PD‑1/PD‑L1 therapy.
  • The regimen was well tolerated and generated survivin‑specific T‑cell increases, supporting advancement toward Phase 3 development and broader partnership opportunities.

Key Details

  • Study Design: Open‑label Phase 2 trial evaluating MVP‑S + pembrolizumab + low‑dose cyclophosphamide in advanced/metastatic bladder cancer patients, including those previously progressed on anti‑PD‑1/PD‑L1 therapy.
  • Patient Cohort: 17 evaluable subjects.
  • Efficacy Outcomes:
  • 2 confirmed complete responses (CR).
  • 3 partial responses (PR).
  • All five responders demonstrated durable clinical benefit; one patient remained on treatment > 18 months.
  • Three responders (including both CRs) had prior checkpoint‑inhibitor progression, indicating potential to overcome resistance.
  • Safety/Tolerability: Regimen described as “well tolerated” with no new safety signals reported.
  • Immunological Findings: Increases in survivin‑specific T cells observed in peripheral blood, consistent with DPX platform mechanism of targeted cytotoxic T‑cell activation.
  • Strategic Implications: Results reinforce synergistic potential of MVP‑S with anti‑PD‑1 therapy; company plans to advance MVP‑S toward Phase 3 in ovarian cancer and explore additional indications/partnering opportunities.
  • Market Context: Highlights upcoming patent expirations for major PD‑1/PD‑L1 antibodies (Keytruda, Opdivo, Libtayo, Tecentriq, Imfinzi) by 2028–2032, creating a commercial opportunity for MVP‑S.
  • Pipeline Update: BioVaxys also cited positive data in HR(+)/HER2(−) breast cancer, non‑muscle invasive bladder cancer, relapsed/refractory diffuse large B‑cell lymphoma, and recurrent epithelial ovarian cancer.

Notable Quotes

“The encouraging activity—including complete responses in checkpoint‑refractory patients—highlights survivin as a compelling target and strengthens the rationale for advancing MVP‑S toward Phase 3 development in ovarian cancer and exploring broader partnering opportunities across additional indications.” – Kenneth Kovan, President & COO, BioVaxys Technology Corp.

Read the original news release →

More from BioVaxys Technology Corp.